Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From the Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept AFFINITY Study
Objective Assess guselkumab+golimumab combination versus guselkumab monotherapy in participants with active PsA and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (≥3 tender/swollen joints) were randomized (2:1) to subcu…